Skip to main
ANIK

Anika Therapeutics (ANIK) Stock Forecast & Price Target

Anika Therapeutics (ANIK) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anika Therapeutics has demonstrated strong financial performance, with its Integrity product line achieving over 100% revenue growth forecasted for 2025 compared to 2024. The company's regenerative solutions business, particularly driven by the Integrity patch, reported a notable 41% growth in the recent quarter, contributing positively to overall revenue. Additionally, international osteoarthritis pain revenue showed a robust 21% increase year-over-year, indicating a favorable market response and expanding global presence.

Bears say

Anika Therapeutics Inc reported a revenue decline of 5.9% to $27.8 million in the latest period, indicating ongoing financial challenges as it excludes recent divestitures. The company's gross margin fell to 56%, below expectations, mainly due to persistent production yield issues, which have also impacted international osteoarthritis pain revenue, leading to a 10% decrease year-over-year. Over the last 12-18 months, the company has faced a series of adverse developments, resulting in a negative outlook for its stock performance.

Anika Therapeutics (ANIK) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anika Therapeutics (ANIK) Forecast

Analysts have given Anika Therapeutics (ANIK) a Buy based on their latest research and market trends.

According to 1 analysts, Anika Therapeutics (ANIK) has a Buy consensus rating as of Dec 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anika Therapeutics (ANIK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.